生物加工
临床前试验
3D生物打印
生物医学
药物开发
药剂学
药品
三维模型
计算机科学
医学
纳米技术
药理学
计算生物学
组织工程
生物信息学
生物医学工程
生物
医学物理学
材料科学
人工智能
作者
Renjian Xie,Vaibhav Pal,Yanrong Yu,Xiaolu Lu,Mengwei Gao,Shijie Liang,Miao Huang,Weijie Peng,İbrahim T. Özbolat
出处
期刊:Biomaterials
[Elsevier BV]
日期:2023-11-27
卷期号:304: 122408-122408
被引量:17
标识
DOI:10.1016/j.biomaterials.2023.122408
摘要
The limitations of traditional two-dimensional (2D) cultures and animal testing, when it comes to precisely foreseeing the toxicity and clinical effectiveness of potential drug candidates, have resulted in a notable increase in the rate of failure during the process of drug discovery and development. Three-dimensional (3D) in-vitro models have arisen as substitute platforms with the capacity to accurately depict in-vivo conditions and increasing the predictivity of clinical effects and toxicity of drug candidates. It has been found that 3D models can accurately represent complex tissue structure of human body and can be used for a wide range of disease modeling purposes. Recently, substantial progress in biomedicine, materials and engineering have been made to fabricate various 3D in-vitro models, which have been exhibited better disease progression predictivity and drug effects than convention models, suggesting a promising direction in pharmaceutics. This comprehensive review highlights the recent developments in 3D in-vitro tissue models for preclinical applications including drug screening and disease modeling targeting multiple organs and tissues, like liver, bone, gastrointestinal tract, kidney, heart, brain, and cartilage. We discuss current strategies for fabricating 3D models for specific organs with their strengths and pitfalls. We expand future considerations for establishing a physiologically-relevant microenvironment for growing 3D models and also provide readers with a perspective on intellectual property, industry, and regulatory landscape.
科研通智能强力驱动
Strongly Powered by AbleSci AI